MetaCap

Enlivex (ENLV) vs XORTX Therapeutics (XRTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Enlivex is the larger company by market cap ($2.0 million vs $1.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ENLV+242.69%XRTX-51.92%
+823%+365%-94%
Oct 7, 20261 yearNov 20, 2026
ENLV+313.39%XRTX-40.50%
+633%+280%-73%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ENLV versus XRTX key metrics
MetricENLVXRTX
Share price$1.05$0.839
Market cap$2.01M$1.88M
1-day change-11.76%-5.73%
P/E ratio (TTM)0.00—
Forward P/E—1.05
EPS (TTM)$7,904.00$-2.09
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$1.24B—
52-week high$434.40$3.60
52-week low$1.00$0.81
Distance from 52-week high-99.76%-76.69%
Analyst consensusnone—
Avg. price target upside+7519.05%—
Average volume73.14K776.48K
Shares outstanding1.91M2.25M
Employees34—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Enlivex

ENLV stock →

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2.

Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees

About XORTX Therapeutics

XRTX stock →

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney.

Health Care · Biotechnology: Pharmaceutical Preparations

ENLV vs XRTX FAQ

Which is bigger, Enlivex or XORTX Therapeutics?

Enlivex (ENLV) is larger, with a market capitalization of $2.01M compared with $1.88M for XORTX Therapeutics (XRTX).

Are Enlivex and XORTX Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons